Amova Asset Management Americas Inc. Sells 205,564 Shares of CRISPR Therapeutics AG $CRSP

Amova Asset Management Americas Inc. trimmed its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,958,111 shares of the company’s stock after selling 205,564 shares during the quarter. CRISPR Therapeutics makes up about 1.2% of Amova Asset Management Americas Inc.’s portfolio, making the stock its 24th biggest position. Amova Asset Management Americas Inc.’s holdings in CRISPR Therapeutics were worth $102,605,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the company. Capital International Investors grew its holdings in CRISPR Therapeutics by 4.3% during the 4th quarter. Capital International Investors now owns 5,892,745 shares of the company’s stock valued at $309,016,000 after purchasing an additional 243,487 shares during the last quarter. State Street Corp grew its holdings in CRISPR Therapeutics by 35.6% during the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after purchasing an additional 859,334 shares during the last quarter. Orbis Allan Gray Ltd grew its holdings in CRISPR Therapeutics by 76.9% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock valued at $134,467,000 after purchasing an additional 1,201,600 shares during the last quarter. UBS Group AG grew its holdings in CRISPR Therapeutics by 7.7% during the 4th quarter. UBS Group AG now owns 2,524,144 shares of the company’s stock valued at $132,366,000 after purchasing an additional 180,580 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in CRISPR Therapeutics by 2.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,364,645 shares of the company’s stock valued at $153,253,000 after purchasing an additional 66,556 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $51.48 on Wednesday. The company has a 50 day moving average price of $52.23 and a 200-day moving average price of $53.11. CRISPR Therapeutics AG has a fifty-two week low of $39.81 and a fifty-two week high of $78.48. The stock has a market capitalization of $4.97 billion, a PE ratio of -8.28 and a beta of 1.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 17.96 and a current ratio of 17.97.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The business had revenue of $1.46 million during the quarter. Equities analysts predict that CRISPR Therapeutics AG will post -4.92 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 3,182 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $46.78, for a total transaction of $148,853.96. Following the completion of the sale, the general counsel owned 94,308 shares of the company’s stock, valued at $4,411,728.24. This represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Naimish Patel sold 3,786 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the sale, the insider directly owned 19,357 shares of the company’s stock, valued at $1,076,636.34. The trade was a 16.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 33,937 shares of company stock valued at $1,646,126. Company insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $110.00 price objective (up from $105.00) on shares of CRISPR Therapeutics in a research report on Tuesday, March 17th. TD Cowen boosted their price objective on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a research report on Friday, February 13th. Evercore reissued an “outperform” rating and issued a $76.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, May 11th. Morgan Stanley reissued an “underweight” rating and issued a $33.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. Finally, Sanford C. Bernstein boosted their price objective on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $65.47.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.